MedTrace Logo

Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia

NCT07323095 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-04-22

No results posted yet for this study

Summary

This is a phase 2, international, multicenter, randomized, double blind, placebo-controlled trial to evaluate the efficacy and safety of ABP-671 in subjects with CKD and hyperuricaemia, to preliminarily evaluate the efficacy of ABP-671 in the treatment of subjects with CKD and hyperuricemia, primary Efficacy Endpoint is change in UACR from baseline to Week 40

Conditions

Interventions

DRUG

ABP-671 plus febuxostat Group 1

ABP-671 Dose 1 + Febuxostat Dose 1-tablets(PO)

DRUG

ABP-671 plus febuxostat Group 2

ABP-671 Dose 2 + Febuxostat Dose 2-tablets(PO)

DRUG

ABP-671 Group

ABP-671 Dose 2 + Febuxostat placebo-tablets(PO)

DRUG

Placebo Group

ABP-671 placebo-tablets(PO) + Febuxostat placebo-tablets(PO)

Sponsors & Collaborators

  • Atom Therapeutics Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2027-10-31
Completion
2028-01-31

Countries

  • Australia
  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07323095 on ClinicalTrials.gov